Boston Sci Coated Stent Program Progressing Despite Medinol Stalemate

Boston Scientific's ongoing negotiations to buy out Israeli partner Medinol and its Nir line of coronary stents will not interfere with the firm's development of its drug-eluting stent program for in-stent restenosis should the talks falter.